443 related articles for article (PubMed ID: 23747022)
21. Profiling in resolving inflammatory exudates identifies novel anti-inflammatory and pro-resolving mediators and signals for termination.
Norling LV; Serhan CN
J Intern Med; 2010 Jul; 268(1):15-24. PubMed ID: 20497301
[TBL] [Abstract][Full Text] [Related]
22. Vacuolar (H
Rao Z; Pace S; Jordan PM; Bilancia R; Troisi F; Börner F; Andreas N; Kamradt T; Menche D; Rossi A; Serhan CN; Gerstmeier J; Werz O
J Immunol; 2019 Aug; 203(4):1031-1043. PubMed ID: 31300512
[TBL] [Abstract][Full Text] [Related]
23. Developments of specialized pro-resolving mediators in periodontitis.
Liu YC
Hua Xi Kou Qiang Yi Xue Za Zhi; 2021 Feb; 39(1):94-98. PubMed ID: 33723943
[TBL] [Abstract][Full Text] [Related]
24. Vagus nerve controls resolution and pro-resolving mediators of inflammation.
Mirakaj V; Dalli J; Granja T; Rosenberger P; Serhan CN
J Exp Med; 2014 Jun; 211(6):1037-48. PubMed ID: 24863066
[TBL] [Abstract][Full Text] [Related]
25. Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors.
Chiang N; Serhan CN
Mol Aspects Med; 2017 Dec; 58():114-129. PubMed ID: 28336292
[TBL] [Abstract][Full Text] [Related]
26. Lipid mediators in the resolution of inflammation.
Serhan CN; Chiang N; Dalli J; Levy BD
Cold Spring Harb Perspect Biol; 2014 Oct; 7(2):a016311. PubMed ID: 25359497
[TBL] [Abstract][Full Text] [Related]
27. Roles, Actions, and Therapeutic Potential of Specialized Pro-resolving Lipid Mediators for the Treatment of Inflammation in Cystic Fibrosis.
Recchiuti A; Mattoscio D; Isopi E
Front Pharmacol; 2019; 10():252. PubMed ID: 31001110
[TBL] [Abstract][Full Text] [Related]
28. Resolvins, Protectins, and Maresins: DHA-Derived Specialized Pro-Resolving Mediators, Biosynthetic Pathways, Synthetic Approaches, and Their Role in Inflammation.
Ferreira I; Falcato F; Bandarra N; Rauter AP
Molecules; 2022 Mar; 27(5):. PubMed ID: 35268778
[TBL] [Abstract][Full Text] [Related]
29. Specialized pro-resolving mediators in cardiovascular diseases.
Fredman G; Spite M
Mol Aspects Med; 2017 Dec; 58():65-71. PubMed ID: 28257820
[TBL] [Abstract][Full Text] [Related]
30. The novel lipid mediator PD1
Hansen TV; Dalli J; Serhan CN
Prostaglandins Other Lipid Mediat; 2017 Nov; 133():103-110. PubMed ID: 28602942
[TBL] [Abstract][Full Text] [Related]
31. Biology and Total Synthesis of n-3 Docosapentaenoic Acid-Derived Specialized Pro-Resolving Mediators.
Reinertsen AF; Vik A; Hansen TV
Molecules; 2024 Jun; 29(12):. PubMed ID: 38930898
[TBL] [Abstract][Full Text] [Related]
32. Maresins: Specialized Proresolving Lipid Mediators and Their Potential Role in Inflammatory-Related Diseases.
Tang S; Wan M; Huang W; Stanton RC; Xu Y
Mediators Inflamm; 2018; 2018():2380319. PubMed ID: 29674943
[TBL] [Abstract][Full Text] [Related]
33. Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators.
Serhan CN
Prostaglandins Leukot Essent Fatty Acids; 2008; 79(3-5):157-63. PubMed ID: 19008087
[TBL] [Abstract][Full Text] [Related]
34. Deciphering the role of n-3 polyunsaturated fatty acid-derived lipid mediators in health and disease.
Spite M
Proc Nutr Soc; 2013 Nov; 72(4):441-50. PubMed ID: 23991833
[TBL] [Abstract][Full Text] [Related]
35. Prostanoids and Resolution of Inflammation - Beyond the Lipid-Mediator Class Switch.
Schmid T; Brüne B
Front Immunol; 2021; 12():714042. PubMed ID: 34322137
[TBL] [Abstract][Full Text] [Related]
36. Lipid mediators of inflammation and Resolution in individuals with tuberculosis and tuberculosis-Diabetes.
Shivakoti R; Dalli J; Kadam D; Gaikwad S; Barthwal M; Colas RA; Mazzacuva F; Lokhande R; Dharmshale S; Bharadwaj R; Kagal A; Pradhan N; Deshmukh S; Atre S; Sahasrabudhe T; Kakrani A; Kulkarni V; Raskar S; Suryavanshi N; Chon S; Gupte A; Gupta A; Gupte N; Arriaga MB; Fukutani KF; Andrade BB; Golub JE; Mave V
Prostaglandins Other Lipid Mediat; 2020 Apr; 147():106398. PubMed ID: 31726221
[TBL] [Abstract][Full Text] [Related]
37. Role of Specialized Pro-Resolving Mediators in Modifying Host Defense and Decreasing Bacterial Virulence.
Thornton JM; Yin K
Molecules; 2021 Nov; 26(22):. PubMed ID: 34834062
[TBL] [Abstract][Full Text] [Related]
38. Pro-resolving mediators produced from EPA and DHA: Overview of the pathways involved and their mechanisms in metabolic syndrome and related liver diseases.
López-Vicario C; Rius B; Alcaraz-Quiles J; García-Alonso V; Lopategi A; Titos E; Clària J
Eur J Pharmacol; 2016 Aug; 785():133-143. PubMed ID: 25987424
[TBL] [Abstract][Full Text] [Related]
39. Resolution of Inflammation after Skeletal Muscle Ischemia-Reperfusion Injury: A Focus on the Lipid Mediators Lipoxins, Resolvins, Protectins and Maresins.
Barnig C; Lutzweiler G; Giannini M; Lejay A; Charles AL; Meyer A; Geny B
Antioxidants (Basel); 2022 Jun; 11(6):. PubMed ID: 35740110
[TBL] [Abstract][Full Text] [Related]
40. The biosynthetic pathways of the protectins.
Stenvik Haatveit Å; Hansen TV
Prostaglandins Other Lipid Mediat; 2023 Dec; 169():106787. PubMed ID: 37806439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
